T1	Participants 48 77	patients with type 2 diabetes
T2	Participants 211 240	Patients with type 2 diabetes
T3	Participants 580 610	patients with type 2 diabetes.
T4	Participants 1549 1569	514 of 2605 patients
T5	Participants 1852 1919	301 patients in the pioglitazone group and 358 in the placebo group
T6	Participants 2410 2439	patients with type 2 diabetes
